DealSpexis sells antibiotics programme to BasileaMacrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd. more ➔
financingFinnish Enifer Oy secures €12m grant to scale upMicrobial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually. more ➔
financingMogu Srl raises €11m to scale mycelium technologyItalian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC) more ➔
FinancingNovo Nordisk Foundation in US$25m partnership with CARB-XNovo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections. more ➔
M&ANovartis AG to buy immunology specialist Calypso Biotech BVCalypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175. more ➔
ObesityGLP1 agonists: FDA investigates suicide riskFollowing in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters. more ➔
DealBoehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd. more ➔
FinancingmiRNA specialist Resalis Therapeutics Srl raises €10m in Series A financingItalian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity. more ➔
AMRRoche presents restistance-breaking antibioticHoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii. . more ➔
CollaborationAlfasigma SpA signs €170m deal with Galapagos NVFollowing its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal. more ➔
